Free Trial

OPKO Health (OPK) Competitors

OPKO Health logo
$1.47 0.00 (0.00%)
Closing price 01/17/2025 04:00 PM Eastern
Extended Trading
$1.48 +0.02 (+1.02%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPK vs. FOLD, LGND, GERN, MNKD, DVAX, BCRX, CLDX, NVAX, MYGN, and INVA

Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Myriad Genetics (MYGN), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.

OPKO Health vs.

Amicus Therapeutics (NASDAQ:FOLD) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.

Amicus Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

OPKO Health has a net margin of -18.65% compared to Amicus Therapeutics' net margin of -21.21%. OPKO Health's return on equity of -9.76% beat Amicus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amicus Therapeutics-21.21% -15.97% -3.17%
OPKO Health -18.65%-9.76%-6.46%

64.6% of OPKO Health shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 47.3% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Amicus Therapeutics received 24 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 73.10% of users gave Amicus Therapeutics an outperform vote while only 65.54% of users gave OPKO Health an outperform vote.

CompanyUnderperformOutperform
Amicus TherapeuticsOutperform Votes
530
73.10%
Underperform Votes
195
26.90%
OPKO HealthOutperform Votes
506
65.54%
Underperform Votes
266
34.46%

Amicus Therapeutics has higher earnings, but lower revenue than OPKO Health. Amicus Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$399.36M7.04-$151.58M-$0.34-27.68
OPKO Health$711.41M1.41-$188.86M-$0.19-7.74

In the previous week, OPKO Health had 4 more articles in the media than Amicus Therapeutics. MarketBeat recorded 12 mentions for OPKO Health and 8 mentions for Amicus Therapeutics. OPKO Health's average media sentiment score of 1.07 beat Amicus Therapeutics' score of 0.25 indicating that OPKO Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amicus Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
OPKO Health
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Amicus Therapeutics currently has a consensus price target of $16.88, indicating a potential upside of 79.33%. OPKO Health has a consensus price target of $2.75, indicating a potential upside of 87.07%. Given OPKO Health's stronger consensus rating and higher probable upside, analysts clearly believe OPKO Health is more favorable than Amicus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78
OPKO Health
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

OPKO Health beats Amicus Therapeutics on 12 of the 18 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPK vs. The Competition

MetricOPKO HealthPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.00B$6.22B$5.21B$9.14B
Dividend YieldN/A2.94%5.13%4.02%
P/E Ratio-7.749.8789.3417.36
Price / Sales1.41309.211,240.0477.11
Price / CashN/A61.4443.7535.97
Price / Book0.826.055.314.79
Net Income-$188.86M$154.90M$122.54M$225.00M
7 Day Performance-3.92%-0.32%0.59%2.62%
1 Month Performance-4.55%0.43%2.55%3.81%
1 Year Performance47.44%3.08%25.29%20.10%

OPKO Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPK
OPKO Health
4.4666 of 5 stars
$1.47
flat
$2.75
+87.1%
+47.4%$1.00B$863.50M0.003,930Positive News
FOLD
Amicus Therapeutics
4.3834 of 5 stars
$8.91
-1.2%
$16.88
+89.4%
-21.8%$2.66B$493.67M-26.21480Analyst Revision
LGND
Ligand Pharmaceuticals
4.9596 of 5 stars
$105.34
-0.9%
$147.00
+39.5%
+54.3%$1.99B$152.42M41.9780
GERN
Geron
3.6266 of 5 stars
$2.84
-10.4%
$7.25
+155.3%
+52.9%$1.72B$29.48M-8.8870
MNKD
MannKind
3.3654 of 5 stars
$6.18
+1.5%
$9.07
+46.8%
+78.9%$1.70B$267.20M88.29400
DVAX
Dynavax Technologies
4.5392 of 5 stars
$12.60
-0.2%
$22.00
+74.6%
-10.8%$1.66B$260.81M96.93350
BCRX
BioCryst Pharmaceuticals
4.2653 of 5 stars
$7.96
+3.8%
$15.17
+90.5%
+31.4%$1.65B$412.58M-13.05530Short Interest ↓
CLDX
Celldex Therapeutics
1.5898 of 5 stars
$24.34
0.0%
$62.25
+155.8%
-40.5%$1.61B$9.98M-9.47150
NVAX
Novavax
4.0183 of 5 stars
$8.63
-7.3%
$17.83
+106.6%
+107.4%$1.38B$847.25M-3.821,990
MYGN
Myriad Genetics
4.0794 of 5 stars
$14.14
-4.7%
$24.27
+71.7%
-39.0%$1.29B$823.60M-10.882,700
INVA
Innoviva
1.6569 of 5 stars
$17.50
+1.3%
N/A+14.3%$1.10B$352.75M25.36100Positive News

Related Companies and Tools


This page (NASDAQ:OPK) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners